AMT-061 Increases FIX Activity, Reduces Bleeding in Phase 3 Trial, Data Show

AMT-061 Increases FIX Activity, Reduces Bleeding in Phase 3 Trial, Data Show

Hemophilia News Today

Image

Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL